In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

mRNA: The Future Beyond COVID Vaccines

Executive Summary

Messenger RNA (mRNA) prophylactic vaccines have made major breakthroughs in 2020 and 2021 with both the Pfizer/BioNTech and Moderna COVID-19 vaccines gaining approval in more than 150 countries. These mRNA COVID vaccines have been developed much faster and with superior clinical profiles when compared to other more conventional modalities.

You may also be interested in...



Building On Successes During Turbulent Times, SR One Closes $600m Fund II

SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.

Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues

Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.

Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business

Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel